A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte counts; coagulation, blood gas/ electrolyte/ urinalysis, cells/ microorganisms, including particle counter/analyzer CDA-1000/1000B, an equipment which is capable of counting cells, yeast, algae, bacteria, and others. The company serves national and other public hospitals, general hospitals, universities, research institutes, other medical institutions, etc. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
Financial Summary
| Share Statistics | SSMXY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,078.0 | $337.2 | 70% |
|
| Shares Out (Mil) | 3.9 | 41.9 | 12% |
|
| Institutional Ownership | 41.4% | 77.8% | 18% |
|
| Float (Mil) | 508.7 | 34.7 | 86% |
|
| Beta | 0.68 | 0.85 | 39% |
|
| Avg Daily Volume (000s) | 45 | 278 | 27% |
|
| Price Change (52-week) |
(39.6%) | 58.7% | 20% |
|
| Growth | SSMXY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.7% | 11.8% | 26% |
|
| Net Income (5yr) | (5.7%) | (5.8%) | 33% |
|
| EPS (5yr) | (5.6%) | 11.4% | 24 |
|
| Dividends (5yr) | 0.9% | 0.0% | 61% |
|
| Cash Flow (5yr) | (20.6%) | (16.3%) | 32% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SSMXY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,145 | $152 | 67% |
|
| Net Income (TTM) (Mil) | $223 | ($10) | 69% |
|
| EPS (TTM) | $0.358 | ($0.500) | 51% |
|
| Operating Cash Flow (TTM) (Mil) | $464 | ($2) | 71% |
|
| Net Cash Flow (TTM) (Mil) | $287 | $1 | 87% |
|
| Long-Term Debt (Q1) (Mil) | $383 | $22 | 56% |
|
| Enterprise Value (Q1) (Mil) | $6,121 | $304 | 66% |
|
| Valuation | SSMXY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.80 | na |
|
| P/E | na | 31.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | SSMXY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 51.1% | 59.1% | 63% |
|
| Net Margin | 7.1% | (7.3%) | 55% |
|
| ROA | 5.2% | (13.7%) | 73% |
|
| ROE | 7.4% | (15.8%) | 50% |
|
| Liabilities to Assets | 28.5% | 44.7% | 20% |
|
| F-Score | na | 4 | na |
|
Sysmex Corporation did not pass any screens on 7/31/2026.
